CONSOLIDATED STATEMENTS OF CASH FLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 29, 2014	Mar. 30, 2013	Mar. 31, 2012
Cash Flows from Operating Activities:
Net income	$ 35,148	$ 38,800	$ 66,886
Non-cash items:
Depreciation and amortization	81,740	65,481	49,966
Amortization of financing costs	1,505	1,139	0
Stock compensation expense	13,081	10,969	9,286
Deferred tax expense	(202)	589	5,878
Purchased in process research and development	3,569	0	0
Loss on sale of property, plant and equipment	293	351	772
Unrealized (gain)/loss from hedging activities	(128)	700	166
Changes in fair value of contingent consideration	45	0	(2,154)
Asset write-down	2,587	4,247	0
Change in operating assets and liabilities:
Decrease/(increase) in accounts receivable, net	6,154	(38,080)	(10,539)
Increase in inventories	(12,684)	(18,685)	(32,528)
(Increase)/decrease in prepaid income taxes	1,175	(4,025)	3,058
Decrease/(increase) in other assets and other long-term liabilities	3,176	(6,187)	3,156
Tax benefit of exercise of stock options	1,649	4,194	1,958
Increase in accounts payable and accrued expenses	2,416	25,581	19,413
Net cash provided by operating activities	139,524	85,074	115,318
Cash Flows from Investing Activities:
Capital expenditures on property, plant and equipment	(73,648)	(62,188)	(53,198)
Proceeds from sale of property, plant and equipment	488	1,968	1,002
Acquisition of Whole Blood Business	0	(535,175)	0
Acquisition of Hemerus	(23,124)	(1,000)	0
Other acquisitions	(9,546)	0	0
Net cash used in investing activities	(105,830)	(596,395)	(52,196)
Cash Flows from Financing Activities:
Payments on long-term real estate mortgage	(964)	(886)	(815)
Net (decrease)/increase in short-term loans	(5,521)	7,446	(288)
Term loan borrowings	0	475,000	0
Payments on long-term real estate mortgage	(37,063)	0	0
Debt issuance costs	0	(5,467)	0
Proceeds from employee stock purchase plan	5,229	4,142	3,723
Proceeds from exercise of stock options	15,224	27,517	15,475
Excess tax benefit on exercise of stock options	2,395	4,101	1,433
Share repurchase	0	(50,000)	(49,998)
Net cash (used in)/provided by financing activities	(20,700)	461,853	(30,470)
Effect of exchange rates on cash and cash equivalents	355	(273)	(498)
Net Increase/(Decrease) in Cash and Cash Equivalents	13,349	(49,741)	32,154
Cash and Cash Equivalents at Beginning of Year	179,120	228,861	196,707
Cash and Cash Equivalents at End of Year	192,469	179,120	228,861
Non-cash Investing and Financing Activities:
Transfers from inventory to fixed assets for placement of Haemonetics equipment	10,584	21,677	18,333
Supplemental Disclosures of Cash Flow Information:
Interest paid	8,942	5,910	414
Income taxes paid	$ 1,493	$ 13,178	$ 10,764